Pattern Recognition Part 2

Chapter 090: Pattern Recognition Part 2 At 4:45 PM, Catherine Marsh found the FDA letter because she was supposed to be looking for ordinary regulatory risk. That was what made the danger useful and what made it dangerous. The file sat inside ThorneVault under Costa Holdings - FDA Correspondence, plain enough for any competent analyst to open, but buried beneath enough subfolders that only someone mapping the healthcare portfolio would reach it before the report deadline. Leah kept one hand on the mouse and one on Catherine's notebook while the first line loaded: discrepancies between reported Phase III trial data and raw patient records. Sofia had been right. NexGen was not only messy. NexGen had already been noticed. She did not move for three seconds. Around her, the thirty-fourth floor kept breathing: keyboards, low calls, printers, a burst of laughter from the market-intelligence row. Catherine Marsh had to look like a junior analyst finding support material for a landscape analysis. Isabella Thorne wanted to stand up, find Martha, and ask how many crimes could fit inside one acquisition. Leah opened the letter. January 2023. FDA inspection team. Sixty days to provide additional documentation. The language was formal, but the pressure underneath it was not. The agency had seen a mismatch between reported results and raw patient records in NexGen's Phase III trial. If Costa Holdings had known that before closing and failed to disclose it to investors, the problem was not reputational. It was federal. She searched FDA response NexGen. Three documents returned. The first was a Pemberton & Croft legal memo to Costa Holdings, advising a response strategy. The second was Costa's formal answer, dated March 2023, requesting an extension and promising supplemental clinical data. The third was an internal email chain. Leah opened the chain last, because people hid most when they thought lawyers had already shaped the record. The most recent email came from Antonio Costa to Sebastian Costa, Howard Pemberton, and Martha Thorne. Its subject line was ordinary: NexGen - FDA Correspondence. The body was not. Catherine, Per our conversation this morning, I have instructed Pemberton to handle the FDA response. Sebastian will coordinate with NexGen's clinical team to ensure the additional data is comprehensive. The acquisition timeline remains unchanged. We close by end of Q2. I trust this matter will be resolved discreetly. Antonio. Leah read it twice. Antonio had addressed Martha as Catherine, the family name used when outsiders might see a thread. He had copied Sebastian and Pemberton. He had left no doubt that all four knew before the acquisition closed. The last sentence did the work of a confession without using a criminal word: resolved discreetly. She bookmarked the letter, the memo, the response, and the chain under the official analysis project. Then she made Catherine write the obvious business note in careful, harmless language: FDA correspondence suggests data-integrity risk could affect acquisition timeline and investor disclosure obligations. Only after that did Leah write the real note in the Moleskine, shielded by her left forearm. FDA inspection Jan 2023 confirms NexGen data discrepancy. Antonio/Sebastian/Pemberton/Martha aware. P&C manages response. Timeline unchanged. Possible securities fraud if undisclosed. Her pulse stayed steady. That was the reward Martha had given her by teaching her to read consequence before emotion. A securities case had a different center of gravity from foundation self-dealing. The Strategic Initiatives Fund could cripple Martha's architecture. The FDA chain could put Sebastian and Antonio under federal pressure fast enough to make them careless. At 5:10, David Choi stopped beside her desk. "How is the landscape coming?" Leah clicked back to a public industry report without hurrying. "The portfolio is broader than the onboarding packet suggested. I'm adding a regulatory-risk section so the acquisition history doesn't read like pure market share." David looked at the screen, then at the neat outline beside her keyboard. "Good. Priya likes risk framed early. Don't overstate it unless you can support it." "Understood." He lingered half a beat too long. "Anything unusual?" Catherine's face offered him a small professional frown. "A lot of aggressive acquisitions. Nothing I would call unusual yet." David accepted the answer because it sounded cautious. He moved on. Leah waited until he was three desks away before she exhaled. The small victory was not that she had found the email. It was that she had survived the first question after finding it. She stayed until 5:32, long enough to look diligent and not long enough to seem hungry. On the elevator down, Rachel Okonkwo entered on thirty-six and stood beside her without speaking. Their reflections appeared in the brass doors: Catherine with her tote, Rachel with her laptop bag, both looking forward. "You found the correspondence folder," Rachel said softly. Leah did not turn. "I found several correspondence folders." "Some are safer than others." "I'm preparing a market analysis." "Then make sure your market analysis does not ask why legal handled a clinical question before the clinical team did." The elevator slowed. Rachel's eyes stayed on the doors. "That question gets noticed." The doors opened on thirty-four for two departing managers, then closed again. Leah's throat tightened around a dozen possible answers. She chose the only one Catherine could afford. "Thank you for the caution." Rachel stepped out in the lobby ahead of her and disappeared into the evening crowd without looking back. Ally or test. Door or trap. But Rachel knew exactly which folder mattered. By 6:45, Leah was back in the apartment with the blinds half closed and her phone on the counter. She could not take the FDA chain to a regulator herself. Catherine Marsh was a false identity inside Thorne Group systems. A filing traced to her would destroy the cover and poison the evidence. She needed a conduit with standing, lawyers, and independent access. She needed Ethan Hunt, which was its own kind of risk. The call went to voicemail. "I need to meet," she said. "Tomorrow evening, if possible. I've found something." She ended the call before she could say more. Then she opened the Moleskine and wrote the day in two columns: what Catherine could defend and what Isabella could use. Veritas: sixty-seven million in Foundation program-related investments. NexGen: FDA notice, Pemberton response, Antonio email, acquisition timeline unchanged. Rachel: thirty-sixth floor, Veritas history, now FDA warning. Physical records: pre-2015 missing, likely archive or Hamptons. At the bottom, she wrote one sentence and underlined it once. Evidence without a lawful channel is only exposure risk. The apartment was quiet enough that she could hear the refrigerator cycle on. Somewhere above Park Avenue, Martha Thorne still believed Catherine Marsh was a useful junior analyst. Somewhere inside Hunt Capital, Ethan had built an investigation that had missed the Foundation's visible layer because Martha had hidden it in compliance language instead of secrecy. Leah sent one text at noon the next day after Ethan still had not answered: Central Park, 72nd Street entrance, 7 PM. Bring a coat. If he came, the alliance would need rules before it needed evidence. If he did not, Catherine Marsh would have to find another door before David or Rachel decided she had opened too many.